Skip to main content
PEPTARA LABS
Get Started

Semaglutide Results Timeline

Semaglutide Results Timeline: What STEP 1 Measured

Published by · Updated · How we research and check our pages

The short answer

The semaglutide results timeline below comes from STEP 1, a 68-week randomized trial in 1,961 adults with overweight or obesity (Wilding et al., 2021). Weight fell gradually instead of in a sudden drop, the group mean reached about -15.3 kg by week 68, and about half of participants reached at least 15 percent loss. Everything here is a reported group average from one study, not a promise for any single person.

This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.

Key findings at a glance

  • In the STEP 1 trial, adults taking semaglutide lost a mean of 15.3 kg over 68 weeks versus 2.6 kg with placebo (Wilding et al., 2021).
  • Weight came off gradually, not in a burst: the group-average line kept declining the whole way to week 68 rather than dropping early and leveling off (Wilding et al., 2021).
  • Half of the semaglutide group (50.5 percent) reached at least 15 percent weight loss by week 68, versus 4.9 percent on placebo (Wilding et al., 2021).
  • Research suggests weight loss on GLP-1 therapy tends to slow toward a plateau rather than continue without limit (Guo et al., 2025).
  • After treatment stopped in the STEP 1 extension, participants regained about two-thirds of the lost weight within a year (Wilding et al., 2022).

What is the semaglutide results timeline from the STEP 1 trial?

It is the reported group-average weight change measured across 68 weeks in STEP 1, one large randomized trial of semaglutide (Wilding et al., 2021).

STEP 1 enrolled 1,961 adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, and without type 2 diabetes. Participants were randomized 2 to 1 to semaglutide or placebo, and both groups also followed a reduced-calorie diet and increased physical activity (Wilding et al., 2021). Everything below describes what that population did on average. These are reported group means from one study, not a promise for any single person.

How did weight change week by week across the 68 weeks?

Weight declined gradually the whole way through, steep in the middle stretch and flattening near the end (Wilding et al., 2021).

The reported group-mean weight trend across the trial looked like this:

Trial periodReported group-mean weight trend
First part of the trialweight begins to fall
Through to week 68decline continues, then flattens toward the end
Week 68 (endpoint)mean of about -15.3 kg versus -2.6 kg with placebo

Source: Wilding et al., 2021.

How much weight did the semaglutide group lose overall?

The semaglutide group lost a mean of 15.3 kg, about 14.9 percent of body weight, versus 2.6 kg, about 2.4 percent, with placebo over 68 weeks (Wilding et al., 2021).

That works out to a difference of roughly 12.4 percentage points between the two groups at week 68 (Wilding et al., 2021). The trial also reported improvements in waist circumference and several cardiometabolic markers alongside the weight change (Wilding et al., 2021).

What share of participants reached each weight-loss milestone?

More than eight in ten reached at least 5 percent loss, and half reached at least 15 percent (Wilding et al., 2021).

Weight-loss milestone by week 68SemaglutidePlacebo
At least 5 percent86.4 percent31.5 percent
At least 10 percent69.1 percent12.0 percent
At least 15 percent50.5 percent4.9 percent

Source: Wilding et al., 2021.

About a third of the semaglutide group reached 20 percent or more (Wilding et al., 2021). The spread across these milestones is the point: the 15.3 kg mean sits on top of a wide range of individual outcomes, so a group average does not describe what one person will do.

Why does the weight-loss curve slow down and plateau?

Weight loss on GLP-1 therapy typically decelerates over time and settles toward a plateau, partly because the body's energy use adapts as weight falls (Guo et al., 2025; Rosenbaum and Leibel, 2010).

In STEP 1 the group-mean curve was still declining late in the trial but was flatter near week 68 than at the midpoint (Wilding et al., 2021). A model-based meta-analysis of GLP-1 therapy reported that the time to reach an efficacy plateau varied by drug, from about 17 weeks for liraglutide to about 46 weeks for the dual agonist tirzepatide, the slowest; the same analysis reported that semaglutide had not yet reached its plateau by 52 weeks (Guo et al., 2025; Obesity Pillars 2025; doi:10.1016/j.obpill.2025.100162). Adaptive thermogenesis, the drop in energy expenditure that follows weight loss, is one reported reason the pace slows (Rosenbaum and Leibel, 2010; Int J Obes 2010).

What happened after participants stopped semaglutide?

In the STEP 1 extension, participants regained about two-thirds of their lost weight within a year of stopping the drug and the lifestyle program (Wilding et al., 2022).

Cardiometabolic markers that had improved also moved back toward baseline (Wilding et al., 2022). A similar regain pattern after withdrawing a GLP-1-class drug was reported for tirzepatide in SURMOUNT-4 (Aronne et al., 2024). The takeaway from the data is that the reported timeline reflects continued treatment, and the trajectory changed after treatment ended.

How does the semaglutide timeline compare with tirzepatide?

Separate trials reported larger group-mean loss for tirzepatide, but the studies used different designs and populations, so the timelines are not directly comparable (Jastreboff et al., 2022; Frias et al., 2021).

SURMOUNT-1 reported up to about 22.5 percent mean weight loss with tirzepatide in adults with obesity and without diabetes (Jastreboff et al., 2022), while SURPASS-2 studied tirzepatide against semaglutide in adults with type 2 diabetes, a different population and setting from STEP 1 (Frias et al., 2021). Newer class data, such as retatrutide reporting up to about 24.2 percent at 48 weeks, sits in yet another trial design (Jastreboff et al., 2023). Cross-trial numbers are useful for context, not for a like-for-like race.

Semaglutide Results Timeline: FAQ

How fast does semaglutide work in the STEP 1 trial?

Weight came off gradually rather than in a single rush. In the trial, the group-average weight kept falling across the full 68 weeks instead of dropping early (Wilding et al., 2021).

Did every participant lose about 15 kg?

No. The 15.3 kg figure is a group mean, so individual results in the trial varied widely: about half reached at least 15 percent loss, while others lost less (Wilding et al., 2021).

How long was the STEP 1 trial?

It ran for 68 weeks, with a reduced-calorie diet and more physical activity in both the semaglutide and placebo arms (Wilding et al., 2021).

Does weight loss keep going forever?

Research suggests weight loss on GLP-1 therapy tends to slow toward a plateau rather than continue without limit (Guo et al., 2025).

What happens to weight after stopping?

In the STEP 1 extension, participants regained about two-thirds of their lost weight within a year of stopping the drug and lifestyle program (Wilding et al., 2022).

Is the semaglutide timeline the same as tirzepatide?

No. Separate trials reported larger group-mean loss for tirzepatide, but they used different designs and populations, so the timelines are not directly comparable (Jastreboff et al., 2022; Frias et al., 2021).

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.

Chat with us